{"id":24355,"date":"2022-09-28T10:00:44","date_gmt":"2022-09-28T08:00:44","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=24355"},"modified":"2022-11-03T11:17:41","modified_gmt":"2022-11-03T10:17:41","slug":"first-patient-in-phase-2b-trial","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/","title":{"rendered":"First patient in phase 2b trial"},"content":{"rendered":"\n<p>Evaxion Biotech has announced that the first patient has been enrolled in the company&#8217;s Phase 2b clinical trial of EVX-01 for the treatment of melanoma.<\/p>\n\n\n\n<p><em>Evaxion Biotech: Ticker: EVAX | Price: USD 2.4 | Market Cap.: USD 79M | YTD price development: -46%<\/em><\/p>\n\n\n\n<p>Evaxion Biotech is a Danish biotech company listed in the US, which develops immunotherapies (treatment that helps the patient&#8217;s own immune system to find, attack and destroy e.g. cancer cells, viruses and bacteria) to treat:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Cancer (PIONEER platform)<\/li><li>Infectious diseases, including bacterial (EDEN platform)<\/li><li>Viral diseases (RAVEN platform)<\/li><\/ul>\n\n\n\n<p>Initiation of Phase IIb study of EVX-01 (metastatic melanoma) in collaboration with Merck has been seen as the first of several potential upsides, which are an important part of the investment case in Evaxion.<\/p>\n\n\n\n<p><a href=\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech\/\">View Kapital Partner&#8217;s investment case on Evaxion Biotech here<\/a><\/p>\n\n\n\n<p><strong>Phase 2b clinical trial with EVX-01<\/strong><\/p>\n\n\n\n<p>The first patient has been enrolled in Evaxion&#8217;s Phase 2b clinical trial, which includes approximately 100 patients. Data from the Phase 1\/2a EVX-01 study showed that 6 out of 9 patients (67%) benefited from EVX-01 in combination with a PD-1 inhibitor (KEYTRUDA\u00ae) for the treatment of melanoma. Historical data show that the response rate is only 40% when a PD-1 inhibitor is given alone. The task for Evaxion is therefore to show the increased response rate when EVX-01 is combined with a PD-1 inhibitor also holds true in a larger study. Evaxion Biotech expects to report preliminary data on the ongoing study in H2 2023.<\/p>\n\n\n\n<p>More potential price triggers may be triggered in 2nd half of 2022:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>H2 2022: Phase I application for EVX-03 (lung cancer)<\/li><li>H2 2022: Phase I application for EVX-B1 (antibiotic resistant staphylococci)<\/li><li>H2 2022: Selection of first candidate from RAVEN platform (virus vaccine)<\/li><li>H1 2023: Results from phase 1\/2a study of EVX-02 (treatment of moles cancer after surgery)<\/li><\/ul>\n\n\n\n<p><strong>Price development for Evaxion Biotech (-46%) vs. KPHC-index year to date<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1173\" height=\"679\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/image-95.png\" alt=\"\" class=\"wp-image-24361\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/image-95.png 1173w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/image-95-300x174.png 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/image-95-768x445.png 768w\" sizes=\"(max-width: 1173px) 100vw, 1173px\" \/><figcaption>The KPHC-index covers all Nordic healthcare stocks<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Evaxion Biotech has announced that the first patient has been enrolled in the company&#8217;s Phase 2b clinical trial of EVX-01 for the treatment of melanoma. Evaxion Biotech: Ticker: EVAX | Price: USD 2.4 | Market Cap.: USD 79M | YTD price development: -46% Evaxion Biotech is a Danish biotech company listed in the US, which [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":22060,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[151,165],"tags":[],"class_list":["post-24355","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-cases","category-investment-cases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>First patient in phase 2b trial | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First patient in phase 2b trial | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Evaxion Biotech has announced that the first patient has been enrolled in the company&#8217;s Phase 2b clinical trial of EVX-01 for the treatment of melanoma. Evaxion Biotech: Ticker: EVAX | Price: USD 2.4 | Market Cap.: USD 79M | YTD price development: -46% Evaxion Biotech is a Danish biotech company listed in the US, which [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T08:00:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-03T10:17:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"537\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"First patient in phase 2b trial\",\"datePublished\":\"2022-09-28T08:00:44+00:00\",\"dateModified\":\"2022-11-03T10:17:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/\"},\"wordCount\":316,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg\",\"articleSection\":[\"Company cases\",\"Investment cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/\",\"name\":\"First patient in phase 2b trial | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg\",\"datePublished\":\"2022-09-28T08:00:44+00:00\",\"dateModified\":\"2022-11-03T10:17:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg\",\"width\":800,\"height\":537},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investment cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Company cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/company-cases\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"First patient in phase 2b trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First patient in phase 2b trial | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/","og_locale":"en_US","og_type":"article","og_title":"First patient in phase 2b trial | Kapital Partner A\/S","og_description":"Evaxion Biotech has announced that the first patient has been enrolled in the company&#8217;s Phase 2b clinical trial of EVX-01 for the treatment of melanoma. Evaxion Biotech: Ticker: EVAX | Price: USD 2.4 | Market Cap.: USD 79M | YTD price development: -46% Evaxion Biotech is a Danish biotech company listed in the US, which [&hellip;]","og_url":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2022-09-28T08:00:44+00:00","article_modified_time":"2022-11-03T10:17:41+00:00","og_image":[{"width":800,"height":537,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"First patient in phase 2b trial","datePublished":"2022-09-28T08:00:44+00:00","dateModified":"2022-11-03T10:17:41+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/"},"wordCount":316,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg","articleSection":["Company cases","Investment cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/","url":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/","name":"First patient in phase 2b trial | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg","datePublished":"2022-09-28T08:00:44+00:00","dateModified":"2022-11-03T10:17:41+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/Evaxion-Biotech-modermaerkekraeft-1.jpg","width":800,"height":537},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/first-patient-in-phase-2b-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investment cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/"},{"@type":"ListItem","position":3,"name":"Company cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/company-cases\/"},{"@type":"ListItem","position":4,"name":"First patient in phase 2b trial"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/24355"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=24355"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/24355\/revisions"}],"predecessor-version":[{"id":24364,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/24355\/revisions\/24364"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/22060"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=24355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=24355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=24355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}